✦ LIBER ✦

Iodine-131-rituximab for relapsed/refractory indolent NHL

Book ID: 120850118
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2006
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200615540-00060

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Iodine-131 tositumomab in refractory NHL

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

Rituximab + DHAP as salvage therapy for

Rituximab + DHAP as salvage therapy for relapsed/refractory NHL

📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Iodine-131 tositumomab promising in refr

Iodine-131 tositumomab promising in refractory NHL

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 156 KB

Radioimmunotherapy with 131I-rituximab f

Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)

✍ Hye J KANG; Seung S LEE; Kyeong M KIM; Tae H CHOI; Gi J CHEON; Won S KIM; Cheolw 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 567 KB

Lenalidomide + rituximab for relapsed/re

Lenalidomide + rituximab for relapsed/refractory MCL

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Mitoxantrone–cyclophosphamide–rituximab:

Mitoxantrone–cyclophosphamide–rituximab: an effective and safe combination for indolent NHL

✍ C. Emmanouilides; M. Territo; H. Menco; R. Patel; P. Rosen 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

## Abstract Treatment for extensive indolent lymphoma should combine optimization of efficacy without excessive toxicity. Rituxan may be an ideal agent for combinations with chemotherapy because of its non‐cross‐resistant toxicity profile and the potential for synergism. We present the results of 3